Drug intelligence / Profile preview

SPRI-919

Development stage: Preclinical
Lead developer: Menarini
Modality: Small Molecules

Overview

SPRI-919 is a developmental-stage pharmaceutical agent that was part of the neuroscience business unit acquired by Assertio Therapeutics from the Menarini Group in early 2023. While specific clinical details and its precise mechanism of action are not widely publicized in standard commercial databases, it is categorized within the neuroscience portfolio, which typically focuses on conditions such as pain management, neurology, or psychiatry. The acquisition by Assertio was intended to diversify their portfolio into hospital and acute care markets, alongside established products like NUZYRA (omadacycline).

Beyond the preview

Go deeper on SPRI-919.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPRI-919.

Explore the full profile